Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Common Equity (2018 - 2026)

Exagen filings provide 9 years of Common Equity readings, the most recent being $14.4 million for Q1 2026.

  • On a quarterly basis, Common Equity rose 125.39% to $14.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $14.4 million, a 125.39% increase, with the full-year FY2025 number at $17.4 million, up 82.9% from a year prior.
  • Common Equity hit $14.4 million in Q1 2026 for Exagen, down from $17.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $76.2 million in Q1 2022 to a low of $6.4 million in Q1 2025.
  • Median Common Equity over the past 5 years was $21.0 million (2025), compared with a mean of $29.0 million.
  • Biggest five-year swings in Common Equity: plummeted 67.97% in 2025 and later surged 125.39% in 2026.
  • Exagen's Common Equity stood at $42.5 million in 2022, then crashed by 46.55% to $22.7 million in 2023, then crashed by 57.96% to $9.5 million in 2024, then skyrocketed by 82.9% to $17.4 million in 2025, then decreased by 17.29% to $14.4 million in 2026.
  • The last three reported values for Common Equity were $14.4 million (Q1 2026), $17.4 million (Q4 2025), and $18.1 million (Q3 2025) per Business Quant data.